Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05864560

Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up

Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up: A Multi-center, Prospective, Single-arm, Open-label, Post-market Study

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
164 (actual)
Sponsor
Lifetech Scientific (Shenzhen) Co., Ltd. · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The objective of the study is to collect real-world data on patient outcomes and evaluate the safety and performance of the Lifetech Ankura™ AAA Stent Graft System, Ankura™ Cuff Stent Graft System, Ankura™ AUI Stent Graft System and ZoeTrack™ Super Stiff Guidewire.

Detailed description

Abdominal aortic aneurysm (AAA) is the most common true arterial aneurysm. Surgical management options for AAA include traditional Open Surgical Repair (OSR) and minimally invasive Endovascular Aneurysm Repair (EVAR). Multiple endovascular devices are commercially available for repair of AAA. Currently available endovascular grafts for infrarenal aortic repair share a bifurcated, modular design. Ankura™ Stent Graft Systems are minimally invasive endovascular devices that offer an alternative treatment for patients with AAA, which have been marketed worldwide for many years. In order to evaluate the long-term safety and performance of the investigational device from real world, this post-market clinical follow-up study is planned under the Regulation (EU) 2017/745. The study intends to enroll 162 subjects. The anticipated enrollment period is approximately 1.5 years and subjects will be followed for 3 years (36 months) post-implantation.

Conditions

Interventions

TypeNameDescription
DEVICEAnkura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft SystemPatients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).

Timeline

Start date
2023-09-19
Primary completion
2026-03-01
Completion
2027-12-01
First posted
2023-05-18
Last updated
2026-03-19

Locations

7 sites across 3 countries: Bulgaria, Greece, Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT05864560. Inclusion in this directory is not an endorsement.